Combination oral contraceptives (OCs) are probably not an independent risk factor for
cardiovascular disease but through their metabolic actions, may partly amplify the effects of …

The many effects that the oestrogens and progestagens used in oral contraceptive (OC) and
postmenopausal hormone replacement therapies (HRTs) have on lipoprotein metabolism …

The study was done to assess the clinical performance and in vivo steroid release rate of 3-
keto-desogestrel subdermal implants designed to deliver 5 different doses of the progestin …

Objective To review the literature to determine the magnitude of the effect of 150 μg
desogestrel-30 μg ethinyl E 2, an oral contraceptive (OC) formulation, on plasma lipid …

The clinical experience with a combined oral contraceptive (COC) containign 150 μg
desogestrel and 30 μg ethinylestradiol is reviewed. Fourteen clinical trials have been …

Thirty postmenopausal women were randomly treated with desogestrel (DG) or
levonorgestrel (LN) 125 μg/day for 3 weeks. Desogestrel reduced the serum total and free …

Abstract Changes in serum lipid and lipoprotein levels were evaluated in a randomized
prospective study conducted in matched healthy young women before and after 6 months' …

The results of a prospective longitudinal controlled study comparing the coagulation effects
of a standard low-dose combined oral contraceptive (Microgynon 30), a desogestrel …

The effects on lipid metabolism of seven combined oral contraceptives were investigated,
particularly the effects on high density lipoprotein (HDL) subfractions, which were separated …

Prostacyclin synthesis is stimulated in vitro by high density lipoproteins (HDL), which
themselves are differently affected by desogestrel (DG)-and levonorgestrel (LN)-containing …